Eisai Co., Ltd. (4523) Stock Price

Eisai has two main business segments: pharmaceuticals and other businesses. The pharmaceutical business involves research and development, manufacturing, and sales of prescription drugs and over-the-counter medicines. This business is organized across five regions: Japan, North America, China, EMEA (Europe, Middle East, Africa, Russia, and Oceania), and East Asia & Global South.

The pharmaceutical business's main products include prescription drugs and over-the-counter medicines. In Japan, Eisai and EA Pharma Co., Ltd. are the principal companies. In North America, Eisai Corporation of North America and Eisai Inc. operate. In China, companies such as Eisai (China) Investment Co., Ltd. are key players.

In the EMEA region, Eisai Europe Ltd. and Eisai GmbH operate as major companies. In the East Asia & Global South region, Eisai Asia Regional Services Pte. Ltd. and Eisai Korea Inc. are principal companies. These subsidiaries support business operations in their respective regions.

The other business segment includes licensing, pharmaceutical raw materials, and business services. In Japan, Eisai and Sunplanet Co., Ltd. operate in this field. These businesses serve as important components supporting Eisai's diversified business operations.

Eisai prioritizes patient and consumer satisfaction and aims to meet the diverse needs of healthcare systems. Under this philosophy, the company has formulated the "Eisai Future Creation Strategy" and addresses social challenges through its pharmaceutical business. The company is particularly focused on creating science and data-driven solutions in the fields of dementia and oncology.

Eisai's medium-term management plan "EWAY Future & Beyond" divides the period into two phases: "EWAY Future" covering fiscal years 2021-2025, and "EWAY Beyond" from fiscal year 2026 onward. The plan aims to support patients and consumers in "living fully." To address unmet medical needs in dementia and oncology, the company is strengthening collaboration with other industries and advancing the development of an hhc ecosystem.

In the dementia field, the company provides solutions for early diagnosis and treatment, with a focus on Alzheimer's disease (AD). Specifically, it is advancing the development and regulatory approval of lecanemab and building a dementia ecosystem. In oncology, the company is expanding treatment options through the development of anticancer agents such as Lenvima.

Eisai is also actively engaged in global health, promoting the development of new drugs for neglected tropical diseases (NTDs), tuberculosis, and malaria. Through these efforts, the company contributes to solving pharmaceutical access challenges and creating social impact.

The company positions employees as important stakeholders and promotes the development of a workplace environment that is easy to work in and respects diversity. Through these initiatives, the company aims to support employee growth and sustainable corporate development, thereby enhancing corporate value.